Medicare's $2,000 Cap: Reducing Prescription Drug Costs for Seniors

Starting in 2025, over 1 million Americans on Medicare will save over $1,000 annually due to a $2,000 cap on out-of-pocket prescription drug costs. This change, part of President Biden's Inflation Reduction Act, will significantly benefit those with high-priced medications. The AARP endorsed this reform and highlighted its positive impact on financial stability for seniors.

In a significant policy shift, more than 1 million Medicare beneficiaries in the U.S. are expected to save over $1,000 annually starting in 2025 due to a $2,000 cap on prescription drug out-of-pocket costs. The cap, part of President Joe Biden's Inflation Reduction Act, applies to Medicare Part D.

The American Association of Retired Persons (AARP) championed the legislation and commissioned Avalere Health to study its impact. AARP's report reveals that the cap will lower prices for over 3.2 million seniors in 2025, representing about 8.4% of Part D beneficiaries without other subsidies.

Previously, Part D enrollees without low-income subsidies paid 5% of drug costs regardless of their total expenditure. This change is anticipated to deliver long-term savings to those who incur high medication costs, despite possible premium increases. By 2029, an estimated 4.1 million beneficiaries will benefit from the cap.